Literature DB >> 10987304

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

L Girard1, S Zöchbauer-Müller, A K Virmani, A F Gazdar, J D Minna.   

Abstract

To identify the major tumor suppressor gene (TSG) loci involved in the pathogenesis of lung cancer, we have conducted a high-resolution (10 cM), genome-wide search of loss of heterozygosity (LOH). Thirty-six lung cancer cell lines [14 small cell lung cancers (SCLCs) and 22 non-SCLCs (NSCLCs)] and their matched control DNAs were analyzed using 399 fluorescent microsatellite markers from the ABI Prism linkage mapping set v.2 on an ABI 377 sequencer/genotyper. Overall, 22 different regions with more than 60% LOH were identified: (a) 13 regions with a preference for SCLC; (b) 7 regions with a preference for NSCLC; and (c) 2 regions affecting both SCLC and NSCLC. The chromosomal arms with the most frequent LOH were 1p, 3p, 4p, 4q, 5q, 8p, 9p (p16), 9q, 10p, 10q, 13q (Rb), 15q, 17p (p53), 18q, 19p, Xp, Xq. In addition, new homozygous deletions were found at 2p23, 8q24, 18q11, and Xq22. On average, 34% (SCLC) to 36% (NSCLC) of markers showed allele loss in individual tumors, with an average size of subchromosomal region of loss of five to six markers (50-60 cM). Whereas SCLC and NSCLC had different regions of frequent LOH (hot spots), and NSCLC had more of these regions (n = 22) than SCLC (n = 17), in all other parameters (fractional allelic loss, number of breakpoints, and number of microsatellite alterations), SCLC and NSCLC were not significantly different. Clustering analysis revealed correlations between LOH on different chromosomes that suggest previously unknown genetic interactions for lung cancer development. We conclude that (a) in lung cancer cell lines, at least 17-22 chromosomal regions with frequent allele loss are involved, suggesting that the same number of putative TSGs are inactivated; (b) SCLC and NSCLC frequently undergo different specific genetic alterations; and (c) clusters of TSGs are likely to be inactivated together. Overall, these data provide global estimates of the extent of genetic changes leading to lung cancer and will be useful for the positional cloning of new TSGs and for the identification of multiple new biomarkers for translational research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987304

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  95 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  A long AAAG repeat allele in the 5' UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells.

Authors:  C L Galindo; J F McCormick; V J Bubb; D H Abid Alkadem; Long-Shan Li; L J McIver; A C George; D A Boothman; J P Quinn; M A Skinner; H R Garner
Journal:  Breast Cancer Res Treat       Date:  2010-12-10       Impact factor: 4.872

3.  Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Authors:  Simone Filosto; Cathleen R Becker; Tzipora Goldkorn
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

Review 4.  [Role of transcription factor AP-1 in integration of cellular signalling systems].

Authors:  K T Turpaev
Journal:  Mol Biol (Mosk)       Date:  2006 Nov-Dec

5.  Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer.

Authors:  Laura T Smith; Mauting Lin; Romulo M Brena; James C Lang; David E Schuller; Gregory A Otterson; Carl D Morrison; Dominic J Smiraglia; Christoph Plass
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

6.  Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation.

Authors:  Kiyomi O Toyooka; Shinichi Toyooka; Anirban Maitra; Qinghua Feng; Nancy C Kiviat; Alice Smith; John D Minna; Raheela Ashfaq; Adi F Gazdar
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 7.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 8.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  Differential expression of inflammasomes in lung cancer cell lines and tissues.

Authors:  Hui Kong; Yanli Wang; Xiaoning Zeng; Zailiang Wang; Hong Wang; Weiping Xie
Journal:  Tumour Biol       Date:  2015-04-25

10.  Decreased expression of KLF6 and its significance in gastric carcinoma.

Authors:  Qing Zhang; Xiao-ping Tan; Yue-sha Yuan; Cheng-ming Hu; Chang-hua He; Wei-zheng Wang; Jun-chuan Li; Qiu Zhao; Nan-zhi Liu
Journal:  Med Oncol       Date:  2009-12-05       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.